Page last updated: 2024-11-04

vorinostat and Aggressive Systemic Mastocytosis

vorinostat has been researched along with Aggressive Systemic Mastocytosis in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Aggressive Systemic Mastocytosis: A form of systemic mastocytosis in which patients have impaired organ functions due to multifocal infiltrates of pathological MAST CELLS in bone marrow, liver, spleen, gastrointestinal tract, or skeletal system. The cytomorphology shows a low to high grade.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lyberg, K1
Ali, HA1
Grootens, J1
Kjellander, M1
Tirfing, M1
Arock, M1
Hägglund, H1
Nilsson, G1
Ungerstedt, J1

Other Studies

1 other study available for vorinostat and Aggressive Systemic Mastocytosis

ArticleYear
Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
    Oncotarget, 2017, Feb-07, Volume: 8, Issue:6

    Topics: Acetylation; Case-Control Studies; Cell Line; Cell Proliferation; Cell Survival; DNA Methylation; Do

2017